

**KIMIA BIOSCIENCES LIMITED**
**Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102**

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com &amp; info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120


**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025**

(₹ Lakhs except EPS)

S. No.	Particulars	Quarter ended			Half Year Ended		Year Ended
		30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operations	3,399.93	2,358.41	2,817.86	5,758.34	5,057.79	11,892.08
II	Other Income	(33.17)	84.69	37.09	51.52	45.42	132.03
III	<b>Total Income (I+II)</b>	<b>3,366.76</b>	<b>2,443.10</b>	<b>2,854.95</b>	<b>5,809.86</b>	<b>5,103.21</b>	<b>12,024.11</b>
IV	<b>Expenses:</b>						
	a) Cost of materials consumed	1,771.04	1,706.19	1,746.35	3,477.23	3,243.57	7,455.02
	b) Change in inventories of finished goods and work-in-progress	474.77	(290.32)	(20.95)	184.45	(295.52)	(368.23)
	c) Employee benefits expenses	330.83	327.67	352.45	658.50	695.28	1,367.89
	d) Finance costs	26.70	174.71	103.93	201.41	214.77	455.70
	e) Depreciation and amortisation expense	97.13	93.53	78.64	190.66	168.42	337.89
	f) Other expenses	571.29	362.18	403.10	933.47	707.06	1,412.42
V	<b>Total Expenses (IV)</b>	<b>3,271.76</b>	<b>2,373.96</b>	<b>2,663.52</b>	<b>5,645.72</b>	<b>4,733.58</b>	<b>10,660.69</b>
VI	<b>Profit/(loss) before exceptional items and Tax (III-V)</b>	<b>95.00</b>	<b>69.14</b>	<b>191.43</b>	<b>164.14</b>	<b>369.63</b>	<b>1,363.42</b>
VII	Exceptional Items	-	-	-	-	-	-
VI	<b>Profit/(loss) before tax (IV-V)</b>	<b>95.00</b>	<b>69.14</b>	<b>191.43</b>	<b>164.14</b>	<b>369.63</b>	<b>1,363.42</b>
VII	<b>Tax expenses:</b>						
	a) Current Tax	-	-	31.95	-	61.69	-
	b) Deferred Tax charge / (credit)	(6.51)	8.74	(1.86)	2.23	2.90	402.18
VIII	<b>Profit/(loss) for the period (VI-VII)</b>	<b>101.51</b>	<b>60.40</b>	<b>161.34</b>	<b>161.91</b>	<b>305.04</b>	<b>961.24</b>
IX	<b>Other Comprehensive Income</b>						
A.	Items that will not be reclassified to Profit or Loss (Net of Tax)						
	- Remeasurement of defined benefit plans	-	-	-	-	-	3.04
B.	Items that will be reclassified to Profit or Loss (Net of Tax)	-	-	-	-	-	(0.77)
X	<b>Total Comprehensive Income for the period (VIII+IX)</b>	<b>101.51</b>	<b>60.40</b>	<b>161.34</b>	<b>161.91</b>	<b>305.04</b>	<b>963.51</b>
XI	Paid up equity share capital (Face value of Rs.1 per equity share)	473.13	473.13	473.13	473.13	473.13	473.13
XII	<b>Other Equity</b>						
XIII	<b>Earnings per equity share (not annualised)</b>						
	Basic in Rs.	<b>0.21</b>	<b>0.13</b>	<b>0.34</b>	<b>0.34</b>	<b>0.64</b>	<b>2.03</b>
	Diluted in Rs.	<b>0.21</b>	<b>0.13</b>	<b>0.34</b>	<b>0.34</b>	<b>0.64</b>	<b>2.03</b>

**Other Notes**

1 The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.

**FOR KIMIA BIOSCIENCES LIMITED**

Date: November 14, 2025

Place: New Delhi

**Sameer Goel**  
 (Managing Director & CEO)  
 DIN - 00161786